Clinical trials: Pediatric All, open to volunteers
Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia
Feasibility and Safety of Donor-derived NK-cell Infusions for Leukemia Relapse Prophylaxis After Hematopoietic Stem Cell Transplantation
This pilot clinical trial aims to evaluate the feasibility, adverse reactions and maximum tolerated dose of mbIL21 ex vivo-expanded donor-derived NK-cell infusions before and after haploidentical or matched-related hematopoietic…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic T-cell Leukemia, Mixed Phenotype Acute Leukemia
- Trial name
- NCT07256210
- Testing
- Donor-derived Natural Killer Cell
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Relapsed/Refractory Pediatric B-ALL
JY509 Universal NK Cell Injection for the Treatment of Relapsed/Refractory Pediatric B-ALL
This is a single-arm, open-label, dose-escalation and expansion, prospective clinical trial conducted in patients with relapsed or refractory pediatric B-cell acute lymphoblastic leukemia to evaluate the safety and efficacy of…
- Trial name
- NCT07406178
- Testing
- JY509 universal NK cell injection
- Volunteers
- 18 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Acute Lymphoblastic Leukemia
Telematic Cognitive Training and Mindfulness in Pediatric Patients After CAR-T Cell Therapy, Single Hematopoietic Allogeneic Transplant or Chemotherapy
This randomized controlled clinical trial evaluates neurocognitive, biopsychological, and brain connectome outcomes in children and adolescents with acute lymphoblastic leukemia who have previously received Chimeric Antigen…
- Trial name
- PsyCARTkids (NCT07479927)
- Testing
- Digital cognitive training, Online Mindfulness-Based Intervention
- Where
- Spain
- Volunteers
- 40 people
- Sponsor
- Hospital Universitario La Paz
Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia
Bridging Allogeneic Hematopoietic Stem Cell Transplantation or Not After CD19 CAR - T (S1904) Cell Therapy for r/r B-cell Acute Lymphoblastic Leukemia
Traditional salvage chemotherapy has low efficacy and poor long-term prognosis for relapsed or refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
- Conditions
- Relapsed Adult ALL, B-cell Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
- Trial name
- NCT06581081
- Testing
- Senl_B19 autologous CAR-T (S1904) treatment
- Where
- China
- Volunteers
- 130 people
- Sponsor
- Peking University People's Hospital
Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL
A Study of pCAR-19B in the Treatment of CD19-positive Relapsed/Refractory B-ALL in Children and Adolescents
This is a phase II clinical study to evaluate the safety and efficacy of pCAR-19 B cell autologous infusion preparation in the treatment of CD19-positive relapsed/refractory B-cell acute lymphoblastic leukemia.
- Conditions
- Acute Lymphoblastic Leukemia, Relapsed Pediatric ALL, Refractory Acute Lymphoblastic Leukemia
- Trial name
- NCT05334823
- Testing
- pCAR-19B cells
- Where
- 16 sites in China
- Volunteers
- 100 people
- Sponsor
- Chongqing Precision Biotech Co., Ltd
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
Substudy 01A: Zilovertamab Vedotin in Pediatric and Young Adult Participants With Hematologic Malignancies or Solid Tumors (MK-9999-01A/LIGHTBEAM-U01)
Substudy 01A is part of a platform study. The purpose of this study is to assess the efficacy and safety of zilovertamab vedotin in pediatric participants with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL)…
- Conditions
- B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma, Burkitt Lymphoma, Neuroblastoma
- Trial name
- NCT06395103
- Testing
- Zilovertamab vedotin
- Where
- 71 sites in United States, Australia and 21 more
- Volunteers
- 90 people
- Sponsor
- Merck Sharp & Dohme LLC
Acute Lymphoblastic Leukemia ALL, Childhood Cancer Survivors
Online Physical Activity and Health Counseling for Survivors of Childhood Acute Lymphoblastic Leukemia
Advances in the medical treatment of childhood acute lymphoblastic leukemia (ALL) have resulted in 5-year survival rates above 90%- however, the success is not without consequences.
- Conditions
- Acute Lymphoblastic Leukemia ALL, Childhood Cancer Survivors, Exercise, Rehabilitation Exercise
- Trial name
- OPAC-ALL (NCT07042932)
- Testing
- Exercise
- Volunteers
- 82 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Asthma, Wheeze
Pediatric Arm of DZL All Age Asthma Cohort
Despite its common occurrence, still little is known about pathomechanisms determining different wheeze and asthma trajectories and phenotypes in children, and those beginning in adulthood.
- Conditions
- Asthma, Wheeze, Hypersensitivity, Endophenotype
- Trial name
- ALLIANCE (NCT02496468)
- Where
- 5 sites in Germany
- Volunteers
- 1,500 people, healthy volunteers welcome
- Sponsor
- LMU Klinikum
Relapsed Pediatric ALL, Hematopoietic Cell Transplantation
CD45RA-depleted CD19-CAR T Cell Consolidation After TCRαβ+/CD19 B Cell-depleted Haploidentical Hematopoietic Cell Transplantation for Relapsed/Refractory CD19+ ALL and Lymphoma
The purpose of this study is to learn more about newer methods of transplanting blood cells donated by a partially matched family member to children with high-risk CD19 positive leukemia ALL.
- Conditions
- Relapsed Pediatric ALL, Hematopoietic Cell Transplantation, Hematologic Malignancy
- Trial name
- NCT07257419
- Testing
- Anti-Thymocyte Globulin (Rabbit), Cyclophosphamide, Fludarabine
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- St. Jude Children's Research Hospital
Pediatric Acute Lymphoblastic Leukemia
Treatment of Newly Diagnosed High Risk Pediatric Acute Lymphoblastic Leukemia
Clinical and genetic factors consistent with High risk : Induction → Consolidation 1. BM MRD \< 0.01% : IM #1 → DI #1 → IM #2 → Maintenance 2. BM MRD ≥ 0.01% : IM #1 → DI #1 → IM #2 → DI #2 → Maintenance 3.
- Trial name
- HR ALL (NCT06184009)
- Testing
- ALL, High risk
- Where
- 9 sites in South Korea
- Volunteers
- 370 people
- Sponsor
- Jae Wook Lee
Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia
Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies
This phase I trial tests the safety, side effects and best infusion dose of genetically engineered cells called anti-CD19/CD20/CD22 chimeric antigen receptor (CAR) T-cells following a short course of chemotherapy with…
- Conditions
- Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia, Recurrent B-Cell Prolymphocytic Leukemia, Recurrent Chronic Lymphocytic Leukemia
- Trial name
- NCT05418088
- Testing
- Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Sumithira Vasu
Pediatric ALL, Sepsis
Evaluation of Pediatric eCART Implementation
This is a study comparing 3 years of retrospective data (pre-implementation) to 2 years of prospective data after the implementation of a pediatric version of Electronic Cardiac Arrest Risk Triage (pediatric eCART), a clinical…
- Trial name
- NCT06771830
- Testing
- Pediatric eCART
- Where
- United States
- Volunteers
- 30,000 people
- Sponsor
- University of Wisconsin, Madison
Acute Lymphoblastic Leukemia, Adult
RWE of Pediatric-like Protocol for AYA Patients With Ph-negative ALL
This is a multicenter, observational real world clinical trial with prospective follow up that will evaluate the treatment outcome of adolescent and young patients with ph-negative acute lymphoblastic leukemia with first-line…
- Trial name
- NCT05127148
- Testing
- Evaluation of survival and toxicities in AYA Ph-negative ALL patients treating in first line depending on risk category.
- Where
- 2 sites in Argentina
- Volunteers
- 100 people
- Sponsor
- Grupo Argentino de Tratamiento de la Leucemia Aguda
ALL, Childhood, Pediatric Cancer
Pharmacogenomic Association Study in Indian Children With Acute Lymphoblastic Leukemia
A five-year prospective observational cohort study. The study is focused on observing the relation between static germline variants and therapeutic response in Indian children with acute lymphoblastic leukemia (ALL).
- Conditions
- ALL, Childhood, Pediatric Cancer, Toxicity, Drug, Adverse Drug Event
- Trial name
- MPGx-INDALL (NCT05512169)
- Where
- 2 sites in India
- Volunteers
- 556 people
- Sponsor
- University of Geneva, Switzerland
Acute Lymphoblastic Leukemia, Pediatric
A Prospective, Open-label, Randomized Controlled, Multicenter Clinical Study of MSD-HSCT Using a TBI or TMLI Conditioning Regimen for Pediatric ALL
This study aims to compare the effects of two different conditioning regimens on patients with acute lymphoblastic leukemia (ALL) undergoing matched sibling donor hematopoietic stem cell transplantation (MSD-HSCT): Total Body…
- Trial name
- NCT06564493
- Testing
- TBI, TMLI, Cyclophosphamide
- Where
- China
- Volunteers
- 170 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
Acute Lymphoblastic Leukemia (ALL) Philadelphia Chromosome-positive (Ph+), Childhood Leukemia, Acute Lymphoblastic
Newly-diagnosed Pediatric Ph-positive B-ALL Protocol
This prospective clinical trial evaluates the effectiveness and safety of "chemotherapy-light" regimen incorporating the third-generation TKI olverembatinib, the bi-specific CD3/CD19 T cell engager blinatumomab, and the BCL-2…
- Trial name
- CAMS-Ph+ B-ALL (NCT07152041)
- Testing
- olverembatinib
- Where
- 24 sites in China, Hong Kong
- Volunteers
- 150 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Virtual Buddy Movement Therapy for Psychomotor and Social Development in Pediatric Oncology Patients in Remission
Acute lymphoblastic leukemia is the most common type of cancer in children diagnosed between the ages of two and five. After cancer treatment, children suffer from fatigue and exhaustion, and thus a decrease in daily physical…
- Trial name
- NCT07522905
- Testing
- Virtual BUDDY-Movement Therapy
- Where
- Slovakia
- Volunteers
- 24 people
- Sponsor
- Comenius University
Acute Lymphoblastic Leukemia
Mercaptopurine Therapeutic Drug Monitoring to Optimize the Maintenance Phase of Childhood ALL
Acute lymphoblastic leukemia (ALL) is the most common hematological malignancy in children (<18 years). The success of pediatric ALL therapy is remarkable but important challenges still need to be faced, including cure rates in…
- Trial name
- NCT05811845
- Where
- 4 sites in Italy
- Volunteers
- 250 people
- Sponsor
- IRCCS Burlo Garofolo
Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive
Study for Safety and Efficacy of Olverembatinib Combined With APG-2575 in Children With Relapsed/Refractory Ph + ALL
This is an open-label, multicenter, phase 1b study, which is designed to explore the safety, efficacy and PK of olverembatinib, a third-generation tyrosine kinase inhibitor (TKI) marketed in China, in combination with APG-2575 in…
- Conditions
- Lymphoblastic Leukemia, Acute, Childhood, Leukemia, Lymphoblastic, Acute, Philadelphia-Positive, Relapsed Leukemia, Refractory Leukemia
- Trial name
- NCT05495035
- Testing
- Olverembatinib, APG-2575, Dexamethasone
- Where
- 4 sites in China
- Volunteers
- 19 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
T-Cell Acute Lymphoblastic Leukemia/Lymphoblastic Lymphoma
CD7-CAR-T Cells in Pediatric Relapsed/Refractory CD7+ T-ALL/LL
The main purpose of this study is to evaluate the safety, to establish the recommended dose, and to evaluate the antitumor effect of CD7-CART01 in pediatric patients with relapsed or refractory (R/R) T-cell acute lymphoblastic…
- Trial name
- CD7-CAR01 (NCT06064903)
- Testing
- CD7-CART01
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Bambino Gesù Hospital and Research Institute